ES2899196T3 - Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK - Google Patents

Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK Download PDF

Info

Publication number
ES2899196T3
ES2899196T3 ES16761176T ES16761176T ES2899196T3 ES 2899196 T3 ES2899196 T3 ES 2899196T3 ES 16761176 T ES16761176 T ES 16761176T ES 16761176 T ES16761176 T ES 16761176T ES 2899196 T3 ES2899196 T3 ES 2899196T3
Authority
ES
Spain
Prior art keywords
amino
mmol
compound
pyrazolo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16761176T
Other languages
English (en)
Spanish (es)
Inventor
Susanta Samajdar
Ramulu Poddutoori
Subhendu Mukherjee
Rajeev Goswami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Ltd filed Critical Aurigene Discovery Technologies Ltd
Application granted granted Critical
Publication of ES2899196T3 publication Critical patent/ES2899196T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16761176T 2015-03-09 2016-03-08 Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK Active ES2899196T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1128CH2015 2015-03-09
PCT/IB2016/051302 WO2016142855A2 (en) 2015-03-09 2016-03-08 Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors

Publications (1)

Publication Number Publication Date
ES2899196T3 true ES2899196T3 (es) 2022-03-10

Family

ID=56879301

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16761176T Active ES2899196T3 (es) 2015-03-09 2016-03-08 Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK

Country Status (7)

Country Link
US (2) US11186576B2 (US07714131-20100511-C00001.png)
EP (1) EP3268000B1 (US07714131-20100511-C00001.png)
JP (1) JP6789962B2 (US07714131-20100511-C00001.png)
CN (1) CN107530329B (US07714131-20100511-C00001.png)
CA (1) CA2978170C (US07714131-20100511-C00001.png)
ES (1) ES2899196T3 (US07714131-20100511-C00001.png)
WO (1) WO2016142855A2 (US07714131-20100511-C00001.png)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3805218A1 (en) * 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3268000B1 (en) * 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
EP3273966B1 (en) * 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
JP7282743B2 (ja) * 2018-03-29 2023-05-29 武田薬品工業株式会社 複素環化合物
KR20200143429A (ko) * 2018-04-11 2020-12-23 주식회사 큐리언트 약학적으로 유효한 피라졸로-트리아진 및/또는 피라졸로-피리미딘 유도체
CN112313235A (zh) * 2018-04-11 2021-02-02 奎利恩特有限公司 作为周期蛋白依赖性激酶的选择性抑制剂的吡唑并-三嗪和/或吡唑并-嘧啶衍生物
EA039950B1 (ru) * 2018-07-20 2022-03-31 Эли Лилли Энд Компани Соединения, пригодные для ингибирования cdk7
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
US11155560B2 (en) 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
WO2020186196A1 (en) * 2019-03-13 2020-09-17 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
CN112125908B (zh) * 2019-06-25 2023-11-03 隆泰申医药科技(南京)有限公司 Cdk激酶抑制剂、其制备方法、药物组合物和应用
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
JP2023507028A (ja) * 2019-12-20 2023-02-20 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 複素環式化合物とその医薬組成物、調製方法、中間体及び使用
CN110950871B (zh) * 2019-12-25 2022-05-17 陕西师范大学 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用
CN111393447B (zh) * 2020-05-14 2021-01-15 苏州信诺维医药科技有限公司 一种嘧啶并吡唑类化合物、其制备方法及应用
TWI783480B (zh) * 2020-05-27 2022-11-11 美商美國禮來大藥廠 用於抑制cdk7之化合物
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
CN114075205A (zh) * 2020-08-12 2022-02-22 隆泰申医药科技(南京)有限公司 Cdk激酶抑制剂、其制备方法、药物组合物和应用
US20240217960A1 (en) * 2021-04-09 2024-07-04 Universität Basel Triazine derivative as covalent inhibitors of pi3k
CN115340524B (zh) * 2021-05-14 2024-05-28 重庆博腾制药科技股份有限公司 一种(s)-去甲烟碱甲基化制备(s)-尼古丁的方法
WO2022266418A1 (en) * 2021-06-17 2022-12-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
CN113801119B (zh) * 2021-08-30 2022-09-30 新乡医学院 一种吡唑并[1,3,5]三嗪类化合物的合成方法
CN114181217B (zh) * 2022-01-10 2022-12-27 陕西师范大学 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用
WO2023227125A1 (zh) * 2022-05-26 2023-11-30 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2024066984A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 三并环类衍生物、药物组合物以及应用
WO2024125532A1 (zh) * 2022-12-12 2024-06-20 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
AP2002002442A0 (en) 1999-08-12 2002-03-31 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their preparation and their use as antitumor agents.
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
MX2007008008A (es) 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
EP2170073A4 (en) * 2007-06-05 2011-07-27 Univ Emory SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES
AU2009266806A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. CDK modulators
FR2943058B1 (fr) 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN105163738A (zh) * 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
EP3805218A1 (en) 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3268000B1 (en) * 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016193939A1 (en) * 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors

Also Published As

Publication number Publication date
US20220281871A1 (en) 2022-09-08
US11186576B2 (en) 2021-11-30
EP3268000A2 (en) 2018-01-17
CN107530329B (zh) 2021-10-08
WO2016142855A2 (en) 2016-09-15
CA2978170C (en) 2024-02-27
US20180258092A9 (en) 2018-09-13
CN107530329A (zh) 2018-01-02
EP3268000B1 (en) 2021-08-04
JP6789962B2 (ja) 2020-11-25
CA2978170A1 (en) 2016-09-15
WO2016142855A3 (en) 2016-11-03
JP2018507877A (ja) 2018-03-22
EP3268000A4 (en) 2018-08-22
US20180057497A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
ES2899196T3 (es) Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
ES2949538T3 (es) Piridazinonas como inhibidores de PARP7
AU2016240033B2 (en) 1-cyano-pyrrolidine compounds as USP30 inhibitors
AU2017287762B2 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
ES2732671T3 (es) Compuestos y composiciones como inhibidores de cinasa C-kit
CN110621675B (zh) 用于治疗增殖性疾病的三环化合物
CA2944669A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN115590854B (zh) 哒嗪基噻唑甲酰胺类化合物
AU2016293441A1 (en) Indazole and azaindazole compounds as IRAK-4 inhibitors
AU2020232026A1 (en) Carboxamide-pyrimidine derivatives as shp2 antagonists
CA2878852A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
AU2014337067A1 (en) Heteroaromatic compounds useful for the treatment of proliferative diseases
CN112584898B (zh) P2x3受体拮抗剂
WO2022266258A1 (en) Compounds and methods for the targeted degradation of irak-4
JP2023540728A (ja) 新規ｐｌｋ１分解誘導化合物
CN117916235A (zh) 周期蛋白依赖性激酶抑制剂
ES2656096T3 (es) Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
JP6522502B2 (ja) Ｗｎｔシグナル阻害剤
EP4389746A2 (en) P2x3 receptor antagonists
WO2024059808A1 (en) Wee1 inhibitors and methods for treating cancer
KR20240027696A (ko) 마크로사이클릭 tak1 억제제
TW202421151A (zh) Ｗｅｅ１抑制劑及用於治療癌症之方法
CN117083272A (zh) 调节nlrp3的4-烷氧基-6-氧代-哒嗪衍生物
CN117980297A (zh) 作为egfr抑制剂的取代的氨基吡啶化合物
TW202330519A (zh) 作為ｔａｍ抑制劑的吡唑并吡啶化合物